Law Offices of Howard G. Smith announces an investigation on behalf of Emergent BioSolutions Inc. (Emergent BioSolutions or the Company) (NYSE: EBS) investors concerning the Companys possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN EMERGENT BIOSOLUTIONS...

The Law Offices of Frank R. Cruz announces an investigation of Emergent BioSolutions Inc. (Emergent BioSolutions or the Company) (NYSE: EBS) on behalf of investors concerning the Companys possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON EMERGENT BIOSOLUTIONS...

Schall, Brown & Schwartz LLP (SBS), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Emergent BioSolutions Inc. (Emergent or the Company) (NYSE: EBS) for violations of the securities laws. INVESTIGATION DETAILS: The investigation...

Emergent BioSolutions (NYSE: EBS) shareholders took losses after the Company disclosed a $191.3 million non-cash impairment on its NARCAN franchise, attributed to increased competition and pricing pressure in naloxone. If you suffered a loss on your Emergent BioSolutions investment, you are...

EBS SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Emergent BioSolutions EBS SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Emergent BioSolutions PR Newswire NEW YORK, Aug. 11, 2026 Emergent...

Shares of Trade Desk, Papa John’s International, Emergent Biosolutions declined after the companies posted disappointing Q2 results last week.

Emergent BioSolutions Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Emergent BioSolutions (EBS) Emergent BioSolutions Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Emergent BioSolutions (EBS) PR Newswire NEW YORK...

Inovio is the most direct hantavirus play based on earlier DNA vaccine studies targeting Andes, Hantaan, and Puumala strains.

Emergent Biosolutions Inc. (NYSE:EBS - Get Free Report) Director Donald Degolyer sold 15,481 shares of the company's stock in a transaction dated Friday, May 1st. The stock was sold at an average price of $8.40, for a total transaction of $130,040.40. Following the completion of the transaction...